Filing Flows

Filing Flows › Companies › Escalon Medical › Cash flow

Escalon Medical cash flow, quarter by quarter

Latest: Q4 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$251K in Q4 FY26

Operating cash flow−$251K
Free cash flow−$251K
Cash / net income-0.1×
Cash conversion cycle75 days

Analysis

In Q4 FY26, Escalon Medical generated −$251K of operating cash flow. That is $263K less than in Q4 FY25 ($12K).

Operating cash flow was −$251K against net income of $1.8M — -0.1× profit, less cash than reported earnings, worth checking against working capital. The largest differences: receivables −$561K, deferred revenue −$102K, prepaid and other assets −$84K.

Its cash conversion cycle was 75 days (receivables 38 + inventory 81 − payables 43).

Free cash flow

Escalon Medical: free cash flow by quarterEscalon Medical: free cash flow by quarter$33KQ1 FY25$301KQ2 FY25$31KQ3 FY25$12KQ4 FY25$81KQ1 FY26−$517KQ2 FY26$281KQ3 FY26−$251KQ4 FY26
Operating cash flow less capital spending.
Escalon Medical: operating cash flow against capital spendingEscalon Medical: operating cash flow against capital spendingOperating cash flowCapital spending$33K$0Q1 FY25$301K$0Q2 FY25$31K$0Q3 FY25$16K$4KQ4 FY25$85K$4KQ1 FY26−$517K$0Q2 FY26$281K$0Q3 FY26−$251K$0Q4 FY26
Latest (Q4 FY26): Operating cash flow −$251K, Capital spending $0.

Capital allocation, year by year

Escalon Medical: where the cash came from (up) and went (down), by fiscal yearEscalon Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingCapital spendingFY22: Operating cash flow −$1.0MFY22: Net borrowing −$3KFY22FY23: Operating cash flow $325KFY23: Net borrowing −$3KFY23: Capital spending −$7K$325KFY23FY24: Operating cash flow −$603KFY24: Net borrowing −$4KFY24: Capital spending −$40KFY24FY25: Operating cash flow $381KFY25: Net borrowing −$3KFY25: Capital spending −$4K$381KFY25FY26: Operating cash flow −$403KFY26: Net borrowing −$3KFY26: Capital spending −$4KFY26
Over these 5 years operating cash flow totalled −$1.3M; the largest uses were operating cash flow ($2.1M) and capital spending ($55K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$3.1M
Debtnone
Net cash$3.1M
Cash runway3.1 years

Escalon Medical is burning cash: its operations consume cash, a free cash flow of −$1.0M a year at the current rate against $3.1M of cash and investments: a runway of about 3.1 years before any new financing.

Where the cash came from and went

Escalon Medical: sources (+) and uses (−) of cash, Q4 FY26Escalon Medical: sources (+) and uses (−) of cash, Q4 FY26Cash drawn (+) / kept (−)$277KOperating cash flow−$251KOther financing−$124KNet borrowing (+) / repaid (−)$123KOther investing−$25K

From profit to cash

Escalon Medical: net income to operating cash flow, Q4 FY26Escalon Medical: net income to operating cash flow, Q4 FY26Net income$1.8MDepreciation & amortization$3KReceivables−$561KInventory−$76KAccrued liabilities$59KDeferred revenue−$102KPrepaid and other assets−$84KOperating cash flow−$251K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q4 FY2638814375
Q3 FY2662865197
Q2 FY2646744971
Q1 FY26491157688
Q3 FY2548834785
Q2 FY2551986485
Q1 FY25671008187

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q4 FY26−$251K—$123K$277K−$251K
Q3 FY26$281K——−$3.0M$281K
Q2 FY26−$517K—−$117K$535K−$517K
Q1 FY26$85K−$4K−$10K−$70K$81K
Q4 FY25$16K−$4K$27K−$5K$12K
Q3 FY25$31K—−$9K−$20K$31K
Q2 FY25$301K—−$9K−$291K$301K
Q1 FY25$33K—−$12K−$21K$33K

Escalon Medical: income statement and cash flow

Escalon Medical, Q4 FY26: revenue $3.9M (+50% year over year), operating margin 14.7%. The chart follows the revenue to costs, profit and cash.

Escalon Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.